



ADMA Biologics, Inc. Class Action Lawsuit - ADMA

ADMA Biologics, Inc.
NASDAQ: ADMA

Affected ADMA Investor Summary

- Who: ADMA Biologics, Inc. ([NASDAQ: ADMA](#))
 - What: Securities fraud class action lawsuit filed
 - Class Period: August 9, 2024 through March 25, 2026
 - Deadline to Seek Lead Plaintiff Status: August 10, 2026
 - Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's revenues and internal controls.
 - Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP](#) (www.ktmc.com) for recovery options
-

The *ADMA Biologics, Inc.* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *ADMA Biologics, Inc.* ("*ADMA Biologics*") (NASDAQ: ADMA) securities between August 9, 2024, and March 25, 2026, inclusive (the "Class Period"). Captioned *Mazzarino v. ADMA Biologics, Inc.*, No. 26-cv-06918 (D.N.J.), the *ADMA Biologics* class action lawsuit alleges that *ADMA Biologics* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *ADMA Biologics* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Najji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than August 10, 2026.

COMPLAINT ALLEGATION SUMMARY:

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

WHY DID ADMA BIOLOGICS' S STOCK DROP?

On March 24, 2026, Culper Research published a report concerning ADMA Biologics alleging "Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported." Among other things, the report stated that "two high-level employees at one of ADMA's two largest distributors" had confirmed independently that, "starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order



expectations", and that "Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there."

On this news, ADMA Biologics' s stock price fell \$3.96, or 29.1%, over two consecutive trading days, to close at \$9.63 per share on March 25, 2026.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *ADMA Biologics* securities during the Class Period to seek appointment as lead plaintiff in the *ADMA Biologics* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

